Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof

Inventors

Chen, Chao-Yi • Tsai, Chih-Chia

Assignees

Taiwan Mercury Medical Corp

Abstract

A metformin tablet, a metformin tablet for relieving pain and reducing inflammation, and a manufacturing method thereof. The tablet for relieving pain and reducing inflammation comprises: a filler, a diluent, an excipient, a binder, a slow-release agent, a sweetener, and a medicinal powder; the excipient comprises: at least one of PVP, PEG, and polymer; the medicinal powder comprises: at least one of metformin and the excipient. The metformin tablet comprises: a hollow part, a thick colloidal layer formed on an outer side of the hollow part, and a powder colloidal layer formed on an outer side of the thick colloidal layer. The tablet for relieving pain and reducing inflammation comprises: a thick colloidal layer, a powder colloidal layer formed on an outer side of the thick colloidal layer, and a hollow part located at a center of the tablet and on an inner side of the thick colloidal layer.

Core Innovation

The invention provides a metformin tablet for relieving pain and reducing inflammation. The tablet includes a hollow part and a layered colloidal structure with a first colloidal layer formed on an outer surface of the hollow part and a second colloidal layer formed on an outer surface of the first colloidal layer. The design ties the layered hollow colloidal structure to a slow-release agent and defined proportions in the first and second colloidal layers.

The first colloidal layer is thicker than the second colloidal layer and is defined as a mixture of a filler, diluent, excipient, binder, slow-release agent, and sweetener in respective weight-percentage ranges. The second colloidal layer is also defined as a mixture of the same categories of components together with medicinal powder. The formulation explicitly uses microcrystalline cellulose and silicified microcrystalline cellulose as the filler; mannitol and a sugar alcohol as the diluent; polyvinylpyrrolidone and polyethylene glycol as the excipient; glucose and lactose as the binder; polylactic acid as the slow-release agent; and isomalt as the sweetener, with metformin as the medicinal powder.

The tablet additionally comprises a disintegrant and a lubricant. The disclosed concept supports a mouth-dissolving dosage form with a smaller tablet size. The described manufacturing guidance forms the hollow center and the two colloidal layers using a cyclic spraying/disposition approach that enables deposition around the hollow part.

Claims Coverage

The document provides one independent claim that specifies a metformin tablet formulation and a hollow, two-layer colloidal structure, including component selection and weight-percentage ranges for each colloidal layer. The independent claim contains three inventive features focused on the layered hollow structure and the defined compositions in the first and second colloidal layers.

Overall, the independent claim defines a metformin tablet with a hollow part and successive first and second colloidal layers, where the first layer is thicker and both layers have specified component categories and weight-percentage ranges, together with medicinal powder, disintegrant, and lubricant.

Stated Advantages

Documented Applications